Abstract:Senolytics are a class of drugs that selectively clear senescent cells (SC). The first senolytic drugs Dasatinib, Quercetin, Fisetin, and Navitoclax were discovered using a hypothesis‐driven approach. SC accumulate with aging and at causal sites of multiple chronic disorders, including diseases accounting for the bulk of morbidity, mortality, and health expenditures. The most deleterious SC are resistant to apoptosis and have up‐regulation of anti‐apoptotic pathways which defend SC against their own inflammatory senescence‐associated secretory phenotype (SASP), allowing them to survive, despite killing neighboring cells. Senolytics transiently disable these SCAPs, causing apoptosis of those SC with a tissue‐destructive SASP. Because SC take weeks to re‐accumulate, senolytics can be administered intermittently – a "hit‐and‐run" approach. In pre‐clinical models, senolytics delay, prevent, or alleviate frailty, cancers, and cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, hematological, metabolic, and skin disorders as well as complications of organ transplantation, radiation, and cancer treatment. As anticipated for agents targeting the fundamental aging mechanisms that are "root cause" contributors to multiple disorders, potential uses of senolytics are protean, potentially alleviating over 40 conditions in preclinical studies, opening a new route for treating age‐related dysfunction and diseases. Early pilot trials of senolytics suggest they decrease senescent cells, reduce inflammation, and alleviate frailty in humans. Clinical trials for diabetes, idiopathic pulmonary fibrosis, Alzheimer's disease, COVID‐19, osteoarthritis, osteoporosis, eye diseases, and bone marrow transplant and childhood cancer survivors are underway or beginning. Until such studies are done, it is too early for senolytics to be used outside of clinical trials.

Discovery of senolytics using machine learning

Senolytic drugs: from discovery to translation

Development of novel flavonoid senolytics through phenotypic drug screening and drug design

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Discovery, development, and future application of senolytics: theories and predictions

Strategies for senolytic drug discovery

Chemoinformatic Screening for the Selection of Potential Senolytic Compounds from Natural Products

Discovery and Repurposing of Multi-Target Senolytics through Structure-Based Virtual Screening

Natural Products as a Major Source of Candidates for Potential Senolytic Compounds obtained by in silico Screening

Aging, Senescent Cells, and Senolytic Drugs: The Path to Translation

Detection of senescence using machine learning algorithms based on nuclear features

Machine learning recognises senescence in glioblastoma and discovers senescence-inducing compounds

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Cellular senescence and senolytics: the path to the clinic

Identification of HSP90 inhibitors as a novel class of senolytics

An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis

Emerging senolytic agents derived from natural products

Insights into targeting cellular senescence with senolytic therapy: The journey from preclinical trials to clinical practice

Connectivity Map and perturbation-based sensitivity analysis identifies MEK inhibitors as senolytics in human lung fibroblasts